$0.32
0.52%
Nasdaq, Apr 21, 08:17 pm CET
ISIN
US01671P1003
Symbol
ALLK
Sector
Industry

Allakos, Inc. Stock price

$0.33
+0.07 28.40% 1M
-0.32 49.85% 6M
-0.88 73.06% YTD
-0.73 69.25% 1Y
-4.55 93.32% 3Y
-62.73 99.48% 5Y
-30.92 98.96% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.00 0.93%
ISIN
US01671P1003
Symbol
ALLK
Sector
Industry

Key metrics

Market capitalization $29.41m
Enterprise Value $-48.72m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.52
P/B ratio (TTM) P/B ratio 0.37
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-118.76m
Free Cash Flow (TTM) Free Cash Flow $-93.74m
Cash position $82.29m
EPS (TTM) EPS $-1.31
P/E forward negative
Short interest 2.36%
Show more

Is Allakos, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Allakos, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Allakos, Inc. forecast:

4x Hold
100%

Analyst Opinions

4 Analysts have issued a Allakos, Inc. forecast:

Hold
100%

Financial data from Allakos, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 7.72 7.72
11% 11%
-
-7.72 -7.72
11% 11%
-
- Selling and Administrative Expenses 31 31
10% 10%
-
- Research and Development Expense 72 72
51% 51%
-
-111 -111
41% 41%
-
- Depreciation and Amortization 7.72 7.72
11% 11%
-
EBIT (Operating Income) EBIT -119 -119
39% 39%
-
Net Profit -116 -116
38% 38%
-

In millions USD.

Don't miss a Thing! We will send you all news about Allakos, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Allakos, Inc. Stock News

Neutral
Business Wire
19 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Allakos Inc. (NASDAQ: ALLK) to Concentra Biosciences, LLC for $0.33 in cash per share is fair to Allakos shareholders. Halper Sadeh encourages Allakos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-00...
Neutral
Business Wire
19 days ago
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Allakos (Nasdaq: ALLK) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer tra...
Neutral
GlobeNewsWire
19 days ago
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merger agreement (the “Merger Agreement”) whereby Concentra Biosciences, LLC ( “Concentra”) will acquire Allakos for $0....
More Allakos, Inc. News

Company Profile

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.

Head office United States
CEO Robert Alexander
Employees 61
Founded 2012
Website www.allakos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today